Active, not recruitingPhase 2NCT01461837

Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

Studying Sickle cell disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
New York Medical College
Principal Investigator
Mitchell S Cairo, MD, MD, MPH
New York Medical College
Intervention
CD34 selected T-cell depleted allogeneic SCT(drug)
Enrollment
21 enrolled
Eligibility
2-20 years · All sexes
Timeline
2012 – 2026

Study locations (6)

Collaborators

UCSF Benioff Children's Hospital Oakland · Medical College of Wisconsin · Washington University School of Medicine · Tufts Medical Center · University of California, San Francisco · University of California, Los Angeles · Miltenyi Biomedicine GmbH · Ann & Robert H Lurie Children's Hospital of Chicago

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01461837 on ClinicalTrials.gov

Other trials for Sickle cell disease

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell disease →

← Back to all trials